Тромботическая тромбоцитопеническая пурпура, ассоциированная с врождённым дефицитом ADAMTS13 Обзор литературы и клиническое наблюдение

Врожденная тромботическая тромбоцитопеническая пурпура (ТТП), известная как синдром Апшоу-Шульмана, является редким наследственным заболеванием, обусловленным дефицитом ADAMTS13. В отличие от приобретенной TTП, при которой имеются аутоантитела к ADAMTS13, у пациентов с синдромом Апшоу-Шульмана отмечается абсолютный врождённый дефицит этой протеазы. Врожденная ТТП обычно проявляется с первых месяцев жизни повторными эпизодами тромбоцитопении и микроангиопатической гемолитической анемии (МАГА). Эти эпизоды, как правило, провоцируются интеркуррентными заболеваниями или физиологическим стрессом. Инфузии свежезамороженной плазмы (СЗП) являются эффективным методом лечения данной болезни, купирующим острые эпизоды и при регулярном применении предотвращающим развитие дальнейших рецидивов. Мы представляем случай 7-летнего мальчика со врожденной ТТП, у которого отмечалось сочетание тромбоцитопении и анемии с первых месяцев жизни. Тем не менее, правильный диагноз был установлен только в возрасте 7 лет. При поступлении в нашу клинику у пациента отмечалась тромбоцитопения, МАГА, повышение уровня креатинина сыворотки и шизоциты в мазке периферической крови. Он получил инфузии СЗП в дозе 10 мл/кг на одно введение, что привело к купированию симптомов. К моменту подготовки данной статьи к печати ремиссия у пациента поддерживалась регулярными инфузиями СЗП в дозе 10 мг/кг каждые 2 недели.

ТТП, ADAMTS13, гемолиз, синдром Апшоу-Шульмана, тромботическая микроангиопатия, TTP, ADAMTS13, hemolysis, Upshaw-Schulman, thrombotic microangiopathy

1. Н.Л. Козловская, Е.Ю. Хафизова, Л.А. Боброва. и др. Роль дефицита ADAMTS13 в развитии тромбозов микроциркуляторного русла почек, не ассоциированных с тромботической тромбоцитопенической пурпурой. Клиническая нефрология. 2011. 6: 25-31.

2. Antoine G, Zimmermann K, Plaimauer B. et al. ADAMTS13 gene defects in two brothers with constitutional thrombotic-thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol. 2003. 120: 821-824.

3. Banno F, Kokame K, Okuda T.et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood. 2006. 107(8): 3161-6.

4. Barbot J, Costa E, Guerra M. et al. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol. 2001. 113: 649.

5. Bennett M, Chubar Y, Gavish I. et al. Experiences in a family with the Upshaw-Schulman syndrome over a 44- year period. Clin Appl Thromb Hemost. 2014. 20: 296.

6. Bernardo A, Ball C, Nolasco L. et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004. 104(1): 100-6.

7. Camilleri RS, Cohen H, Mackie IJ. et al. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost. 2008. 6(2): 331-8.

8. Camilleri RS, Scully M, Thomas M. et al. A phenotype- genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost. 2012. 10(9): 1792-801.

9. Chow TW, Hellums JD, Moake JL. et al. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood. 1992. 80(1): 113-20.

10. Dacie JV, Mollison PL, Richardson N. et al. Atypical congenital haemolytic anaemia. Q J Med. 1953. 22(85): 79-98.

11. De Meyer SF, Savchenko AS, Haas MS. et al. Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood. 2012. 120 (26): 5217-23.

12. Fujikawa K, Suzuki H, McMullen B. et al. Purification of human von Willebrand factor cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001. (6): 1662-6.

13. Fujimura Y, Matsumoto M, Isonishi A. et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011. 9 Suppl 1: 283-301.

14. Fujimura Y, Matsumoto M, Yagi H. et al. Von Willebrand factorcleaving protease and Upshaw-Schulman syndrome. Int J Hematol. 2002. 75(1): 25-34.

15. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996. 87: 4223-4234.

16. Furlan M, Robles R, Morselli B. et al. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 1999. 81(1): 8-13.

17. Furlan M, Robles R, Solenthaler M. et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997. 89(9): 3097-103.

18. Gandhi C, Motto DG, Jensen M. et al. ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. Blood 2012; 120:5224.

19. George JN, Kremer Hovinga JA, Terrell DR. et al. The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry: the Swiss connection. Eur J Haematol. 2008. 80(4): 277-86.

20. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014. 371(7): 654-66.

21. Hassenpflug WA, Budde U, Schneppenheim S. Inherited thrombotic thrombocytopenic purpura in children. Semin Thromb Hemost. 2014. 40(4): 487-92.

22. Kinoshita S, Yoshioka A, Park YD. et al. Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol. 2001. 74(1): 101-8.

23. Kokame K, Kokubo Y, Miyata T. et al. Polymorphisms and mutations of ADAMTS13 in the Japanese population and estimation of the number of patients with Upshaw-Schulman syn- drome. J Thromb Haemost. 2011. 9(8): 1654-6.

24. Kokame K, Matsumoto M, Soejima K. et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A. 2002. 99(18): 11902-7.

25. Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001. 413(6855): 488-94.

26. Lippok S, Radtke M, Obser T. et al. Shear-Induced Unfolding and Enzymatic Cleavage of Full-Length VWF Multimers. Biophys J. 2016. 110(3): 545-54.

27. Loirat C, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura in children. Curr Opin Pediatr. 2013. 25(2): 216-24.

28. Lotta LA, Garagiola I, Palla R. et al. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010. 31(1): 11-9.

29. Lotta LA, Mariani M, Consonni D. et al. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol. 2010. 151(5): 488-94.

30. Lotta LA, Wu HM, Mackie IJ. et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood. 2012. 120(2): 440-8.

31. Ma E, Li YH, Kwok J. et al. ADAMTS13 mutation analysis in Chinese patients with chronic relapsing thrombotic thrombocytopenia purpura. HK J Paediatr. 2006. 11: 22-7.

32. Mansouri Taleghani M, von Krogh AS, Fujimura Y. et al. Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hamostaseologie. 2013. 33(2): 138-43.

33. Mise K, Ubara Y, Matsumoto M. et al. Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19 years: a case report. BMC Nephrol. 2013. 14: 156.

34. Miura M, Koizumi S, Miyazaki H. Thrombopoietin in Upshaw-Schulman syndrome. Blood. 1997. 89(12): 4663-4.

35. Miura M, Koizumi S, Nakamura K. et al. Efficacy of several plasma components in a young boy with chronic thrombocytopenia and hemolytic anemia who responds repeatedly to normal plasma infusions. Am J Hematol. 1984. 17(3): 307-19.

36. Miyata T, Kokame K, Matsumoto M. et al. ADAMTS13 activity and genetic mutations in Japan. Hamostaseologie. 2013. 33(2): 131-7.

37. Moake JL, Rudy CK, Troll JH. et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982. 307(23): 1432-5.

38. Moatti-Cohen M, Garrec C, Wolf M. et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012. 119(24): 5888-97.

39. Monnens LA, Retera RJ. Thrombotic thrombocytopenic purpura in a neonatal infant. J Pediatr. 1967. 71(1): 118-23.

40. Noris M, Bucchioni S, Galbusera M. et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS 13 deficiency and renal involvement. J Am Soc Nephrol. 2005. 16: 1177-1183.

41. Plaimauer B, Kremer Hovinga JA, Juno C. et al. Recombinant ADAMTS13 normalizes von Willebrand factor cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost. 2011: 9:936.

42. Plaimauer B, Scheiflinger F. Expression and characterization of recombinant human ADAMTS-13. Semin Hematol. 2004: 41:24.

43. Plaimauer B, Zimmermann K, Volkel D. et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002. 100(10): 3626-32.

44. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008. 112(1): 11-8.

45. Schiviz A, Wuersch K, Piskernik C. et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood. 2012. 119(25): 6128-35.

46. Schulman I, Pierce M, Lukens A. et al. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood. 1960. 16: 943-57.

47. Scully M, Thomas M, Underwood M. et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014. 124: 211.

48. Siedlecki CA, Lestini BJ, Kottke-Marchant KK. et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996. 88(8): 2939-50.

49. Soejima K, Mimura N, Hirashima M. et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem. 2001. 130(4): 475-80.

50. Tanabe S, Yagi H, Kimura T. et al. Two newborn-onset patients of Upshaw-Schulman syndrome with distinct subsequent clinical courses. Int J Hematol. 2012. 96(6): 789-97.

51. Tsai HM. (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996. 87: 4235-4244.

52. Upshaw Jr JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med. 1978. 298(24): 1350-2.

53. Veyradier A, Lavergne JM, Ribba AS. et al. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost. 2004. 2: 424-429.

54. Von Auer C, von Krogh AS, Kremer Hovinga JA. et al. Current insights into thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and pregnancy. Thromb Res. 2015. 135. Suppl 1: 30-3.

55. Von Krogh AS, Quist-Paulsen P, Waage A. High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence. J Thromb Haemost. 2016. 14(1): 73-82.

56. Wallace DC, Lovric A, Clubb JS. et al. Thrombotic thrombocytopenic purpura in four siblings. Am J Med. 1975. 58(5): 724-34.

57. Williams LA, Marques MB. Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs). Am J Clin Pathol. 2016. 145(2): 158-65.

58. Yagi H, Konno M, Kinoshita S. et al. Plasma of patients with Upshaw-Schulman syndrome, a congenital deficiency of von Willebrand factor-cleaving protease activity, enhances the aggregation of normal platelets under high shear stress. Br J Haematol. 2001. 115(4): 991-7.

59. Zheng X, Chung D, Takayama TK. еt al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001. 276(44): 41059-63.